Shilpa Medicare and Gate2Brain sign strategic equity partnership to advance brain cancer therapy
June 09, 2026 | Tuesday | News
To bring G2B-002 to first-in-human studies and extend its application to other molecules and therapy categories
image credit- freepik
Raichur-based Shilpa Biocare, a subsidiary of Shilpa Medicare, has entered a strategic equity partnership with Spain-based Gate2Brain, S.L., a biotechnology company focused on central nervous system (CNS) therapeutics.
Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead programme targeting deadly paediatric brain cancers, paediatric glioblastoma (pGBM) and diffuse intrinsic pontine glioma (DIPG), both with Orphan Drug Designation from the US FDA and EMA.
G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28.
G2B-002 targets high-growth oncology markets — the glioblastoma market projected at $6.48 billion by 2035 (CAGR: 7.97%), paediatric brain tumours at $2.47 billion by 2031 (CAGR: 6.9%), and DIPG at $1.2 billion by 2035 (CAGR: 7.1%).
Gate2Brain's MiniAp4 platform further extends potential across rare paediatric cancers and broader CNS categories. This marks Shilpa's fourth strategic equity partnership.
